Skip to main content

Table 1 Effect of 5-HT7 receptor signaling on different immune cells and inflammatory conditions

From: Role of 5-HT7 receptors in the immune system in health and disease

Cell Type 5-HT7 Effect
Dendritic cells Induces secretion of IL-1β and IL-8; reduces secretion of IL-12 and TNF-α
Induces process branching and elongation
Monocytes, Macrophagues, Microglia Pro- and anti-inflammatory
Increase in TNF-α, IL-6, Bcl-6, NF-kB
AS-19 (agonist) decreases IL-12, TNF-α, and type 1 interferons; enhances production of TGF-β1
SB-269970 (antagonist) increases TNF-α and IL-12
Lymphocyte Concanavalin A, reserpine, and physical restrain increased expression of 5-HT7
Increase in proliferation rate, expression of CD25
Disease Model 5-HT7 Effect
Inflammatory Bowel Disease 5-HT7 expression increased in DSS-induced colitis
5-HT7 blockade/ablation results in increased severity of acute and chronic colitis
5-HT7 agonists have anti-inflammatory effect
Lung Injury 5-HT7 antagonists decrease lung fluid content, TNF-α, IL-6, oxidative stress in bleomycin-induced lung injury
5-HT7 antagonists reduce collagen deposition, expression of TGF-β1 and procollagen type Ӏ
Central nervous system inflammation LP-211 (agonist) reduces neurotoxic effect of β-amyloid in a model of Alzheimer disease
AS-19 (agonist) reduces pro-apoptotic effect of streptozotocin
Sepsis In LPS-induced sepsis, 5-HT7 mRNA increases in parallel to TNF-α, IL-1β, NF-κB
LP-44 (agonist) attenuates cell injury and reduces iNOS and TNF-α
In a CLP-induced sepsis, AS19 increases survival; reduces tissue injury, inflammatory cytokines, lung NF-κB
Liver Injury 5-HT7 signaling induced during chronic liver injury
Reduced ALT and AST levels
Increased superoxide dismutase
Reduced TNF-α, IL-6, TGF-β1
Soft tissue inflamation In carrageenan-induced paw inflammation, 5-HT7 agonists reduce cyclooxygenase mRNA expression; decrease oxidative stress, serum cytokine levels